title: [Treatment of asthmatic patients with zafirlukast].
abstract: BACKGROUND
  Asthma is a chronic inflammatory illness of the airways in which several cells intervene playing an important role in the development of the bronchial hyperreactivity. Leukotriens are mediators that participate in the inflammatory process.
  
  
  OBJECTIVE
  To value the effectiveness of the zafirlukast in patients with persistent moderate and severe asthma, and to investigate the undesirable effects and the symptoms of intolerance in the study group.
  
  
  METHODS
  The study was carried out on 103 moderate and severe persistent asthmatic patients, with ages between 15 and 50 years, without antecedents of haematological, hepatic or renal diseases, who received 20 milligrams of zafirlukast twice daily during one year. The monitoring was done every month based on its clinical evolution, with control of the renal and hepatic function at the beginning, at six months and at the end of the study. Tests of respiratory function were made at the beginning and the end of the treatment.
  
  
  CONCLUSIONS
  The results show the effectiveness of this medicine, without problems of intolerance or other important secondary adverse effects.
authors.affiliation: Hospital Clínico Quirúrgico Joaquín Albarrán. rosanaranjo@infomed.sld.cu
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Naranjo
authors.forename: Magaly
authors.initials: M
authors.lastname: Olivares Elegia
authors.forename: Roberto Aguila
authors.initials: RA
authors.lastname: de la Coba
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates; D012720:Severity of Illness Index; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; C062735:zafirlukast